Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Anticancer Res ; 42(12): 5991-5997, 2022 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-36456135

RESUMO

BACKGROUND/AIM: Radiotherapy for angiosarcoma of the scalp has not been standardised yet. Hence, we aimed to retrospectively analyse the outcomes of patients treated with electron beam therapy or intensity-modulated radiation therapy (IMRT) for unresectable angiosarcoma of the scalp. PATIENTS AND METHODS: Data from patients treated with chemoradiotherapy or radiotherapy alone for unresectable angiosarcoma of the scalp between March 2009 and March 2021 were evaluated. Survival and local control rates were analysed using the Kaplan-Meier method, and the log-rank test was used to compare groups. Adverse events were analysed using the Common Terminology Criteria for Adverse Events ver. 5.0. RESULTS: Sixteen patients were eligible for the study. Eight patients were treated with electron beam therapy and eight patients with IMRT. The median follow-up period was 18.0 months. The median radiation dose was 57 Gy in 19 fractions in the electron beam therapy group and 70 Gy in 35 fractions in the IMRT group. In the IMRT group, acute non-haematologic toxicity was observed in two patients with grade 3 dermatitis. The one-year overall survival rate, progression-free survival rate, and local control rate in the electron beam therapy group were 80.8%, 56.3%, and 77.4%, respectively, and the corresponding values in the IMRT group were 100%, 75%, and 100%, respectively. One-year local control was significantly better in the IMRT group compared to that in the electron beam therapy group (p=0.016). CONCLUSION: IMRT for angiosarcoma of the scalp may improve local control rates compared to electron beam therapy, but long-term follow-up studies are required to validate this finding.


Assuntos
Hemangiossarcoma , Radioterapia de Intensidade Modulada , Humanos , Hemangiossarcoma/radioterapia , Couro Cabeludo , Radioterapia de Intensidade Modulada/efeitos adversos , Elétrons , Estudos Retrospectivos
2.
J Clin Med ; 11(19)2022 Oct 06.
Artigo em Inglês | MEDLINE | ID: mdl-36233771

RESUMO

External auditory canal (EAC) cancer is a rare disease for which there are no adequate evidence-based treatment strategies. Radiotherapy is often used as the initial treatment to preserve the organ. This study aimed to elucidate the efficacy of radiotherapy for EAC squamous cell carcinoma (SCC). Patients with T1 disease were treated with radiotherapy alone. Patients with T2-4 disease were treated with chemoradiotherapy. The median follow-up period was 30.4 months. The 3-year local control (LC) rate for all patients was 51%, the disease-free survival (DFS) rate was 44%, and the overall survival (OS) rate was 73%. For T1-3 disease, the 3-year LC rate was 74%, DFS was 62%, and OS was 89%. However, for T4 disease, the 3-year LC rate was 17%, DFS was 17%, and OS was 50%. In a univariate analysis, only the T-category was a significant factor for LC and DFS (p = 0.006 and 0.02, respectively). All local recurrences were within the high-dose irradiated area. The results of this study suggest chemoradiotherapy can be an alternative to a combination of surgery and postoperative radiation for T1-3 SCC of the EAC. However, the efficacy of chemoradiotherapy in T4 cases was inadequate.

3.
Anticancer Res ; 42(3): 1439-1446, 2022 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-35220237

RESUMO

BACKGROUND/AIM: Bone and soft-tissue sarcomas of the head and neck have very poor prognoses. This prospective study aimed to investigate the efficacy and safety of carbon-ion radiotherapy (C-ion RT) for bone and soft-tissue sarcoma of the head and neck. PATIENTS AND METHODS: The present study was a prospective clinical study that included 10 consecutive patients diagnosed with bone and soft-tissue sarcoma of the head and neck who were treated with C-ion RT between 2012 and 2018 at our institution. C-Ion RT consisted of 70.4 Gy (relative biological effectiveness) in 16 fractions. RESULTS: The 3-year local control, overall survival, and progression-free survival rates for patients overall were 72.9%, 77.8%, and 36%, respectively. CONCLUSION: The present study demonstrated the efficacy of C-ion RT for bone and soft-tissue sarcoma of the head and neck; adverse events were within the expected range.


Assuntos
Neoplasias de Cabeça e Pescoço/radioterapia , Radioterapia com Íons Pesados , Osteossarcoma/radioterapia , Doses de Radiação , Sarcoma/radioterapia , Adulto , Idoso , Feminino , Neoplasias de Cabeça e Pescoço/mortalidade , Neoplasias de Cabeça e Pescoço/patologia , Radioterapia com Íons Pesados/efeitos adversos , Radioterapia com Íons Pesados/mortalidade , Humanos , Masculino , Pessoa de Meia-Idade , Osteossarcoma/mortalidade , Osteossarcoma/patologia , Intervalo Livre de Progressão , Estudos Prospectivos , Sarcoma/mortalidade , Sarcoma/patologia , Fatores de Tempo , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA